Randomized trial evaluates nuclear PML expression's impact on survival outcomes in localized clear cell renal cell carcinoma, suggesting utility in risk assessment.
Key Points
This research aims to assess nuclear PML expression as a prognostic biomarker in localized clear cell renal cell carcinoma to enhance postoperative risk stratification.
Analyzed two independent retrospective cohorts of patients undergoing surgery for localized ccRCC (n=191, n=173)
Tissue microarrays were stained and assessed for nuclear PML expression using immunohistochemistry
Clinical data and follow-up data were collected with median follow-ups of 8 years and 9 years, respectively.
High nuclear PML expression correlated with improved recurrence-free survival (RFS, p=0.022) and cancer-specific survival (CSS, p=0.027) in the exploratory cohort.
In the validation cohort, high nuclear PML expression was independently linked to improved RFS (HR 0.38, 95% CI 0.21–0.70; p=0.002), CSS (HR 0.30, 95% CI 0.13–0.68; p=0.004), and overall survival (OS, HR 0.34, 95% CI 0.18–0.68; p=0.002).